What Is Pentadeca Arginate (PDA)?

Also known as: PDA peptide

Pentadeca Arginate (PDA) is the same 15-amino-acid sequence as BPC-157, formulated as an arginate salt. It emerged around 2024 as US compounding pharmacies' answer to FDA restrictions on BPC-157 — a chemically distinct salt form of a functionally identical peptide.

Everything known about its effects is borrowed from the BPC-157 literature: tissue repair, gut-lining support and injury recovery in animal models. Vendors claim the arginate form improves solution stability; no published comparison shows any difference in biological effect.

What is Pentadeca Arginate (PDA) studied for?

Side effects & safety

Assumed to mirror BPC-157: mild injection-site reactions, rare nausea. No independent human safety data exists for the arginate form specifically — its track record is even shorter than BPC-157's.

Legal & approval status

Not FDA-approved; circulates through compounding channels and research vendors. Its regulatory position is essentially 'BPC-157 with a different name on the paperwork' — treat legal claims from sellers with skepticism.

Typical dosing at a glance

Commonly reported protocols use 250 mcg–500 mcg, 1–2x daily, via subcutaneous injection. For the mixing math — how much bacteriostatic water, exact syringe units, doses per vial — see the Pentadeca Arginate (PDA) reconstitution calculator →

Related peptides

What is BPC-157?What is TB-500?What is GHK-Cu?What is KPV?

Educational overview based on published research and commonly reported community protocols — not medical advice, and not an endorsement of any compound. Consult a licensed healthcare provider.